Valuation: IO Biotech, Inc.

Market Cap 43.81M 38.94M 36.09M 32.84M 61.97M 4.16B 62.96M 434M 170M 2.17B 164M 161M 6.92B P/E 2023
-0.95x
P/E 2024 -0.63x
Enterprise Value -14.31M -12.72M -11.79M -10.72M -20.24M -1.36B -20.56M -142M -55.55M -709M -53.69M -52.55M -2.26B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99.71%
Yield 2023 *
-
Yield 2024 -
1 day-50.00%
1 week-66.67%
3 months-98.00%
6 months-98.53%
Current year-99.98%
1 week 0
Extreme 1.0E-6
0
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0.7
1 year 0
Extreme 1.0E-6
1.23
3 years 0
Extreme 1.0E-6
2.79
5 years 0
Extreme 1.0E-6
17.88
10 years 0
Extreme 1.0E-6
17.88
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2021-09-30
Compliance Officer 58 2023-01-22
Investor Relations Contact - 2023-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
6/5/25 Free

Director

35,144 0.0533%
6/5/25 Free

Director

35,144 0.0533%
6/5/25 Free

Director

35,144 0.0533%
Change 5-day change 1-year change 3-year change Capi.($)
-50.00%-66.67%-99.98%-99.99% 7.19K
-6.60%-10.93%+45.08%+60.01% 68.98B
-4.09%-0.11%+2.31%+54.81% 53.15B
+0.03%+5.56%+10.18%+41.75% 50.83B
-1.53%+2.70%+29.72%+34.13% 44.61B
-5.97%-6.22%+258.21%+421.57% 40.57B
-1.34%+4.12%+16.05%+112.18% 42.53B
+6.53%+8.02%+18.98%+54.58% 30.95B
-0.90%-10.91%+34.11%-1.83% 25.44B
-2.76%-9.54%-16.53%-9.55% 22.66B
Average -6.69%-5.30%+29.81%+66.77% 37.97B
Weighted average by Cap. -2.47%+1.65%+45.60%+89.53%

Financials

2023 2024
Net sales - -
Net income -86.08M -76.52M -70.92M -64.53M -122M -8.17B -124M -853M -334M -4.26B -323M -316M -13.59B -95.49M -84.88M -78.67M -71.58M -135M -9.06B -137M -946M -371M -4.73B -358M -351M -15.08B
Net Debt -141M -125M -116M -105M -199M -13.35B -202M -1.39B -546M -6.97B -528M -517M -22.21B -58.12M -51.66M -47.88M -43.56M -82.21M -5.52B -83.52M -576M -226M -2.88B -218M -213M -9.18B
Projected Income Statement - Annual - IO Biotech, Inc.
Logo IO Biotech, Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Employees
80
Date Price Change Volume
26-10-15 US$0.000100 -50.00% 6,426
26-10-14 US$0.000200 0.00% 27,540
26-10-13 US$0.000200 -33.33% 12,848
26-10-12 US$0.000300 +50.00% 500
26-10-09 US$0.000200 -33.33% 2,149

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - IO Biotech, Inc.
  1. Stock Market
  2. Stocks
  3. IOBTQ Stock